# US 2014/0154254 A1 · Heterodimeric immunoglobulins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154254 A1
- Document ID: US20140154254A1
- Status: Published application
- Kind: A1
- Application number: 14/086,190
- Filed: 2013-11-21
- Published: 2014-06-05
- Earliest claimed: 2012-11-21
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Gunasekaran Kannan; Monica Florio; Zhi Liu; Wei Yan
- Web page: https://patentgrep.com/patent/US20140154254A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- C07K 16/18: against material from animals or humans
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application is directed to heterodimeric antibodies and methods of use.

## Claims

### Claim 1

A heterodimeric antibody or fragment thereof comprising one or more substitutions in each of the following domains: a first CH3-domain, a second CH3-domain, a CH1-domain, a CL-domain, a VH-domain and a VL-domain,
wherein the one or more substitutions introduce charged amino acids that are electrostatically unfavorable to homodimer formation and electrostatically favorable to heterodimer formation.

### Claim 2 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the first CH3-domain or the second CH3-domain comprises an amino acid sequence differing from wild-type IgG amino acid sequence such that (a) one or more positive-charged amino acids in a wild-type human IgG amino acid sequence are replaced with one or more negative-charged amino acids or (b) one or more negative-charged amino acids in a wild-type human IgG amino acid sequence are replaced with one or more positive-charged amino acids.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the CH1-domain or the CL-domain comprises an amino acid sequence differing from wild-type IgG amino acid sequence such that (a) one or more positive-charged amino acids in wild-type IgG amino acid sequence are replaced with one or more negative-charged amino acids or (b) one or more negative-charged amino acids in wild-type IgG amino acid sequence are replaced with one or more positive-charged amino acids.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the VH-domain or the VL-domain comprises an amino acid sequence differing from wild-type IgG amino acid sequence such that (a) one or more positive-charged amino acids in wild-type IgG amino acid sequence are replaced with one or more negative-charged amino acids or (b) one or more negative-charged amino acids in wild-type IgG amino acid sequence are replaced with one or more positive-charged amino acids.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the positive-charged amino acid is selected from the group consisting of lysine, histidine and arginine.

### Claim 9 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the negative-charged amino acid is selected from the group consisting of aspartic acid and glutamic acid.

### Claim 10 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the first CH3-domain comprises a replacement of a glutamic acid with a positive-charged amino acid.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the first CH3-domain comprises a replacement of an aspartic acid with a negative-charged amino acid.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the second CH3-domain comprises a replacement of a lysine with a negative-charged amino acid.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the CH1-domain comprises a replacement of a serine with a negative-charged amino acid.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the CL-domain comprises a replacement of a serine with a positive-charged amino acid.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the VH-domain comprises a replacement of a glutamine with a negative-charged amino acid.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, wherein the VL-domain comprises a replacement of a glutamine with a positive-charged amino acid.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The heterodimeric antibody or fragment thereof of claim 1, that is selected from the group consisting of an antibody, a bispecific antibody, a monospecific monovalent antibody, a bispecific maxibody, a monobody, a peptibody, a bispecific peptibody, a monovalent peptibody and a receptor fusion protein.

### Claim 25

A heterodimeric antibody or fragment thereof comprising a heavy chain comprising
(a) a first amino acid substitution at an AHo position selected from the group consisting of AHo positions 42-50 that introduces a charged amino acid at said position,
(b) a second amino acid substitution at a position selected from the group consisting of positions 126-213 (EU numbering) that introduces a charged amino acid at said position,
(c) a third amino acid substitution at a position selected from the group consisting of positions 352-360 (EU numbering) that introduces a charged amino acid at said position, and
(d) a fourth amino acid substitution at a position selected from the group consisting of positions 395-403 (EU numbering) that introduces a charged amino acid,
wherein the charged amino acid of (a) has the same charge as the charged amino acid of (b), and wherein the charged amino acids of (c) and (d) have an opposite charge of the charged amino acids of (a) and (b).

### Claim 26 (depends on 25)

The heterodimeric antibody or fragment thereof of claim 25, wherein the first amino acid substitution is at AHo position 46, the second amino acid substitution is at EU position 183, the third amino acid substitution is at EU position 356 and the fourth amino acid substitution is at EU position 399.

### Claim 27 (depends on 25)

The heterodimeric antibody or fragment thereof of claim 25, wherein glutamine at AHo position 46 is replaced with glutamic acid, serine at EU position 183 is replaced with glutamic acid, glutamic acid at EU position 356 is replaced with lysine, and aspartic acid at EU position 399 is replaced with lysine.

### Claim 28

An antibody or fragment thereof comprising a heavy chain comprising
(a) a first amino acid substitution at an AHo position selected from the group consisting of AHo positions 35-43 that introduces a charged amino acid at said position,
(b) a second amino acid substitution at a position selected from the group consisting of positions 126-213 (EU numbering) that introduces a charged amino acid at said position,
(c) a third amino acid substitution at a position selected from the group consisting of positions 388-398 (EU numbering) that introduces a charged amino acid at said position, and
(d) a fourth amino acid substitution at a position selected from the group consisting of positions 404-413 (EU numbering) that introduces a charged amino acid,
wherein the charged amino acids of (c) and (d) have an opposite charge of the charged amino acids of (a) and (b).

### Claim 29 (depends on 28)

The heterodimeric antibody or fragment thereof according to claim 28, wherein the first amino acid substitution is at AHo position 46, the second amino acid substitution is at EU position 183, the third amino substitution is at EU position 393 and the fourth amino acid substitution is at EU position 409.

### Claim 30 (depends on 29)

The antibody or fragment thereof claim 29, wherein glutamine at AHo position 46 is replaced with lysine, serine at EU position 183 is replaced with lysine, lysine at EU position 392 is replaced with aspartic acid and lysine at EU position 409 is replaced with aspartic acid.

### Claim 31

An heterodimeric antibody or fragment comprising a light chain comprising
(a) a first amino acid substitution at an AHo position selected from the group consisting of AHo positions 42-50 that introduces a charged amino acid at said position, and
(b) a second amino acid substitution at a position selected from the group consisting of positions 126-213 (EU numbering) that introduces a charged amino acid at said position.

### Claim 32 (depends on 31)

The heterodimeric antibody or fragment thereof of claim 31, wherein the first amino acid substitution is at AHo position 46 and the second amino acid substitution is at EU position 176.

### Claim 33 (depends on 32)

The heterodimeric antibody or fragment of claim 32, wherein glutamine at AHo position 46 is replaced with glutamic acid and serine at EU position 176 is replaced with glutamic acid.

### Claim 34 (depends on 25)

The heterodimeric antibody or fragment thereof of claim 25, wherein
(a) and (b) have a negative-charge and the charged amino acids of (c) and (d) have a positive charge.

### Claim 35

(canceled)

### Claim 36 (depends on 34)

The antibody or fragment thereof of claim 34, comprising a light chain comprising positive-charged amino acids at AHo position 46 and EU position 176.

### Claim 37

A heterodimeric antibody or fragment thereof comprising a heavy chain comprising
(a) a first amino acid substitution at an AHo position selected from the group consisting of AHo positions 42-50 that introduces a charged amino acid at said position,
(b) a second amino acid substitution at a position selected from the group consisting of positions 126-213 (EU numbering) that introduces a charged amino acid at said position,
(c) a third amino acid substitution at a position selected from the group consisting of positions 388-397 (EU numbering) that introduces a charged amino acid at said position, and
(d) a fourth amino acid substitution at a position selected from the group consisting of positions 404-413 (EU numbering) that introduces a charged amino acid,
wherein the charged amino acids of (a) and (b) have a positive-charge and the charged amino acids of (c) and (d) have a negative-charge.

### Claim 38 (depends on 37)

The heterodimeric antibody or fragment thereof of claim 37, wherein the first amino acid substitution is at AHo position 46, the second amino acid substitution is at EU position 183, the third amino acid substitution is at EU position 392 and the fourth amino acid substitution is at EU position 409.

### Claim 39 (depends on 37)

The heterodimeric antibody or fragment thereof of claim 37, comprising a light chain comprising negative-charged amino acids at AHo position 46 and EU position 176.

### Claim 40 (depends on 26)

The heterodimeric antibody of claim 26 further comprising a second heavy chain and a first light chain and a second light chain, wherein the second heavy chain comprises amino acid substitutions at AHo position 46 and EU positions 183, 392 and 409, and wherein the first and second light chains comprise an amino acid substitution at AHo position 46 and EU position 176, wherein the amino acid substitutions introduce a charged amino acid at said positions.

### Claim 41 (depends on 40)

The heterodimeric antibody of claim 40, wherein glutamine at position AHo 46 of the first heavy chain is replaced with glutamic acid, wherein glutamine at position AHo 46 of the second heavy chain is replaced with lysine, wherein glutamine at position AHo 46 of the first light chain is replaced with lysine, wherein glutamine at position AHo 46 of the second light chain is replaced with glutamic acid, wherein serine at EU position 183 of the first heavy chain is replaced with glutamic acid, wherein glutamic acid at EU position 356 of the first heavy chain is replaced with lysine, wherein glutamic acid at EU position 399 of the first heavy chain is replaced with lysine, wherein serine at EU position 183 of the second heavy chain is replaced with lysine, wherein lysine at EU position 392 of the second heavy chain is replaced with aspartic acid, and wherein lysine at EU position 409 of the second heavy chain is replaced with aspartic acid.

### Claim 42

A heterodimeric antibody that binds sclerostin and DKK-1, comprising
a first heavy chain comprising a variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 378 and 366 and comprising amino acid substitutions at EU positions 183, 356 and 399 of the first heavy chain,
a second heavy chain comprising a variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 1003 and 974 and comprising amino acid substitutions at EU positions 183, 392 and 409 of the second heavy chain,
a first light chain comprising a variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 376 and 364 and comprising an amino acid substitution at EU position 176 of the first light chain, and
a second light chain comprising a variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 1002 and 978 and comprising an amino acid substitution at EU position 176 of the second light chain;
wherein the amino acid substitutions introduce a charged amino acid at said positions.

### Claim 43

(canceled)

### Claim 44

An antibody that binds to a region of sclerostin comprising amino acids 86-111 of SEQ ID NO: 1, wherein the antibody comprises a heavy chain having a CH3 domain comprising one or more amino acid substitutions, wherein the one or more substitutions introduce charged amino acids that are electrostatically unfavorable to homodimer formation and electrostatically favorable to heterodimer formation.

### Claim 45 (depends on 44)

The antibody of claim 44, wherein a negative charged amino acid in the CH3 domain is substituted with a positive charged amino acid.

### Claim 46 (depends on 45)

The antibody of claim 45, wherein the negative charged amino acid is at EU position D399, E356, or E357.

### Claim 47

(canceled)

### Claim 48 (depends on 45)

The antibody of claim 45, wherein the positive charged amino acid is lysine.

### Claim 49 (depends on 44)

The antibody of claim 44, wherein a positive charge amino acid in the CH3 domain is substituted with a negative charged amino acid.

### Claim 50 (depends on 49)

The antibody of claim 49, wherein the positive charged amino acid is at EU position K370, K392 or K409.

### Claim 51

(canceled)

### Claim 52 (depends on 49)

The antibody of claim 49, wherein the negative charged amino acid is aspartic acid.

### Claim 53 (depends on 40)

The heterodimeric antibody of claim 40, wherein the heterodimeric antibody binds to a region of sclerostin comprising amino acids 86-111 of SEQ ID NO: 1, wherein the
first heavy chain and the first light chain comprise a sclerostin-binding portion and the second heavy chain and the second light chain comprise a DKK1-binding portion.

### Claim 54

A heterodimeric antibody that binds to a region of sclerostin comprising amino acids 86-111 of SEQ ID NO: 1, the antibody comprising
a first heavy chain and a first light chain comprising a sclerostin-binding portion and a second heavy chain and a second light chain comprising a DKK1-binding portion, wherein the first heavy chain comprises amino acid substitutions at EU positions 183, 356 and 399, wherein the second heavy chain comprises amino acid substitutions at EU positions 183, 392 and 409, and wherein the first and second light chains comprise an amino acid substitution at EU position 176, wherein the amino acid substitutions introduce a charged amino acid at said positions.

### Claim 55 (depends on 1)

The heterodimeric antibody of claim 1, wherein the antibody binds to a region of sclerostin comprising amino acids 86-111 of SEQ ID NO: 1.

### Claim 56 (depends on 1)

The heterodimeric antibody of claim 1, that is an IgG immunoglobulin.

### Claim 57 (depends on 1)

A nucleic acid comprising a nucleotide sequence encoding the heterodimeric antibody according to claim 1.

### Claim 58 (depends on 57)

A vector comprising the nucleotide sequence of claim 57.

### Claim 59 (depends on 57)

An isolated host cell comprising the nucleic acid of claim 57.

### Claim 60 (depends on 1)

A method of increasing bone mineral density in a mammalian subject comprising administering the heterodimeric antibody of claim 1 to the subject in an amount effective to increase bone mineral density in the subject.

### Claim 61 (depends on 1)

A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier, diluent or adjuvant.

### Claim 62 (depends on 61)

The composition according to claim 61, wherein less than 5% of the antibody in the composition is in aggregate form after two weeks of storage at about 4° C.

### Claim 63

(canceled)

### Claim 64 (depends on 62)

The composition according to claim 62, wherein an amount of antibody in the composition present in aggregate form in determined by Size Exclusion Chromatography.

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)
